CLINICAL FEATURES, TREATMENT RESPONSES, AND OUTCOME OF CHILDREN WITH IDIOPATHIC THROMBOCYTOPENIC PURPURA

Fatih Demircioğlu Department of Pediatric Hematology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey

, MD,

Murat Saygı Department of Pediatrics, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey

, MD,

Şebnem Yılmaz Department of Pediatric Hematology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey

, MD,

Hale Ören Department of Pediatric Hematology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey

, MD &

Gülersu İrken Department of Pediatric Hematology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey

, MD

Pages 526-532 | Received 18 Feb 2008, Accepted 28 Apr 2009, Published online: 08 Oct 2009

Cite this article
https://doi.org/10.1080/08880010903044540

Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions
Read this article /doi/full/10.1080/08880010903044540?needAccess=true

Abstract

The authors investigated demographics, clinical and laboratory features, treatment responses, and outcomes of 93 children (median age 5 years) admitted for idiopathic thrombocytopenic purpura (ITP). The therapy responses of high-dose methylprednisolone (HDMP) (n = 77) and intravenous immunoglobulin (IVIG) (n = 10) treatments were similar. None of the patients with hemorrhage died. Fifteen patients (16.1%) had progressed into chronic ITP. Seven infants had a probable relationship with vaccination; none of these infants progressed into chronic ITP. In conclusion, the overall prognosis in childhood ITP is good. The therapy responses of HDMP and IVIG treatments are similar. Also, ITP cases who havw vaccination history have a benign course.

Keywords:

high-dose methylprednisolone
immune thrombocytopenic purpura
intravenous immunoglobulin
vaccination

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related Research Data

Oral megadose methylprednisolone versus intravenous immunoglobulin for acute childhood idiopathic thrombocytopenic purpura

Source: Informa UK Limited

Intracranial haemorrhage in idiopathic thrombocytopenic purpura. Paediatric Haematology Forum of the British Society for Haematology.

Source: BMJ

The nontreatment of childhood idiopathic thrombocytopenic purpura.

Source: Springer Science and Business Media LLC

Management of childhood idiopathic thrombocytopenic purpura

Source: Wiley

Idiopathic thrombocytopenic purpura in childhood: controversies and solutions.

Source: Wiley

Acute immune thrombocytopenic purpura in infants: associated factors, clinical features, treatment and long-term outcome

Source: Wiley

MMR vaccine and idiopathic thrombocytopaenic purpura

Source: Wiley

Idiopathic thrombocytopenic purpura.

Source: American Academy of Pediatrics (AAP)

Assessment of UK practice for management of acute childhood idiopathic thrombocytopenic purpura against published guidelines

Source: Elsevier BV

Immune Thrombocytopenic Purpura of Childhood

Source: American Society of Hematology

Immune thrombocytopenic purpura.